Showing 1–25 of 28 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Serisha Ramasir, Frasia Oosthuizen, Varsha Bangalee
… of said guidelines. The multi-drug resistant tuberculosis (MDR-TB) guideline has undergone major changes over the past 5 years. These changes included shorter treatment regimens and the introduction of novel drugs. These changes have consequently impacted the management of MDR-T…
Tushar R. Sahasrabudhe
…tional TB Elimination Programme (NTEP) has fixed 2HREZ/4HRE regimen for all drug-sensitive (DS-TB) cases, comprising of isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z). These potent first-line drugs, i.e., HREZ, are the backbone of DS-TB treatment for last man…
Rivaldo Heru Setiawan
…lobal public health challenge, with multidrug-resistant TB (MDR-TB) contributing substantially to poor outcomes. Conventional regimens span 18–24 months, leading to limited adherence and treatment success. Shorter treatment regimens (STRs), such as the BPaL regimen (bedaquiline, …
Tari Nur Fauziyantini, Umi Yuniarni, Lanny Mulqie
…especially in the case of Multidrug-Resistant Tuberculosis (MDR-TB). This study aims to examine the TB-RO therapy regimen that applies in Indonesia through a descriptive analysis approach. The research process was carried out by searching, selecting and analyzing scientific liter…
Piamlarp Sangsayunh, Thanyanuch Sanchat, Charoen Chuchottaworn, Krisana Cheewakul, Sirijit Rattanawai
…nges associated with the implementing of the groundbreaking BPaL-containing regimen in Thailand. Another aim was to investigate the characteristics and severity of the disease, the presence of abnormal extensive lesions in chest X-Rays and the influence of cavitation on sputum co…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Zarir F Udwadia, Jigneshkumar M. Patel
…ease in the number of cases of TB and multi-drug resistant (MDR-TB) has unravelled decades of progress and reflects the profound impact COVID-19 has had on tuberculosis. Despite this grim news, these are exciting times for doctors treating Drug Resistant TB (DR-TB) and for their …
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…XDR-TB are highly DR-TB with a lower success treatment than MDR-TB. Therapy for high DR-TB with fewer drugs and shorter treatment is required to increase the success of treatment. We comprehensively reviewed the risk factors for unfavorable outcomes (death, treatment failure, and…
Carlos Acuña-Villaorduña, Karen R. Jacobson, C. Robert Horsburgh, Martin Canning, Pranay Sinha
Initial experience with BPaL-based regimens to treat multidrug-resistant TB Dear Editor, We read with interest the recent article on the latest WHO guidelines on drug-resistant TB. 1 The recommendation to implement all-oral regimens containing bedaquiline, pretomanid and linezoli…
Oki Nugraha Putra, Telly Purnamasari
…red either a shorter (9 months) or individualized treatment regimen (18 months). However, long treatment duration with various adverse events affects patient compliance. Therefore, a short treatment with less medication is urgently required. In 2022, the WHO announced an alternat…
Tushar Garg
…reatments for complicated multidrug-resistant tuberculosis (MDR-TB) and extensive drug-resistant tuberculosis (XDR-TB), it will be challenging to achieve the World Health Organization (WHO) goal to end the global TB epidemic by 2035. The treatment of MDR- and XDR-TB consists of 4…
Kavitha Saravu, Madhukar Pai
…ant TB (RR-TB), and 82% of them had multidrug-resistant TB (MDR-TB); 3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB. A quarter of the DR-TB cases globally were from India.[1] Only about 25% of these estimated MDR-TB or RR-TB were diagnosed and notified. Th…
Rajendra Prasad, Harsh Saxena, Nikhil Gupta, Mohammad Tanzeem, Ronal Naorem1
… of DR-TB with or without newer anti-TB drugs. multi-DR-TB (MDR-TB) patients have now choice of two types of regimen, shorter and longer regimens. Shorter regimen for treatment of subset of MDR-TB patients who have not been previously treated with second line drugs and in whom re…
Filipa Mota, Camilo A. Ruiz-Bedoya, Elizabeth W. Tucker, Patricia De Jesus, Kelly Flavahan, et al.
…anid is used in combination with bedaquiline and linezolid (BPaL regimen) in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the penetration of pretomanid in privileged sites remain unknown. Antimicrobial pharmacokinetic (PK) parameters are traditionally deri…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Marco Schiuma, Souleymane Hassane Harouna
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023. Only 44% were diagnosed and put on treatment, the therapeutic success rat…
Rafael Laniado-Laborı́n
…l or molecular tests for standardized drug sensitivity. Any regimen for drug-resistant TB is more likely to be effective if its composition is based on information from reliable drug susceptibility testing. The presence of drug-resistant tuberculosis should be suspected in patien…
Christoph Lange, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, Gunar Günther
…G. et al. “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe”, published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Trials group. Availability of drugs and…
Suman Saurabh, Pankaj Bhardwaj
… the recommendation of a shorter all-oral bedaquiline-based regimen for 9–12 months for multidrug or rifampicin-resistant (MDR/RR) tuberculosis, which replaces the current shorter regimen with injectables. The need for a shorter all-oral regimen had been long-felt by experts.[2] …
Michael Ladna
… anastomosis. Case Description/Methods: A man in his 40s on BPAL-M regimen for MDR pulmonary TB presented to Emergency Department with abdominal pain, vomiting, and cessation of bowel movements. Computed tomography abdomen/pelvis showed small bowel obstruction with a terminal ile…
Asan Medical Center
…objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial. The BPaL (Bedaquiline, Pretom…
Galo A. Goig, Chloé Loiseau, Nino Maghradze, Kakha Mchedlishvili, Teona Avaliani, et al.
Abstract Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB are threatening global TB control. The World Health Organization has recently endorsed new regimens for the treatment of MDR-TB that rely on the new and repurposed drugs bedaquiline, pretom…
Karthick Vedi, N Venkateswaramurthy, P. Dineshkumar, Satheesh Nagendrans
…resistant tuberculosis (TB), including multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses major global health challenges. Conventional regimens achieve only 50-60% success rates compared to 85% in drug-susceptible TB. This review examines recent therap…
Jaya Ranjalkar, Premila M Wilfred, R. Lalitha Priya
…tuberculous drug-induced liver injury (ATDILI) for the HRZE regimen was 12.6% (95% CI, 9.9–15.3%, p < 0.001, I2 = 95.1%).4 The median onset time for HRZE associated ATDILI was 3 weeks4 (in 80% of the studies), versus 20 days.1 However, in contrast to this study,1 in India,4 a maj…
Anjali Krishnan P, Praveen Kumar N, Raghul Raj S, Ankit Kumar Bharti S, J. A. Pulatov
…TB Control Program. Results: Among 163 patients, short-term regimens were used in 30 patients (18.2%), including m-STTR (8.5%), m-STTR with delamanide (1.2%), and 6-month BPaLM (8.5%). Long-term standard regimens were used in 53 patients (32.5%). For XDR-TB, BPaL and BPaLC were u…